Abatacept in the treatment of rheumatoid arthritis
Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2006
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936358/ |